Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer
NCT05142696Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2022
- Primary completion
- Mar 2028
- Countries
- 12
01
Overview
Phase 2, randomised trial of lutetium Lu 177 dotatate in small cell lung cancer (SCLC) (8 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 6 weeks and Overall Survival up to 3 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05142696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142696.